abs187.txt	a	hallmark	of	advanced	tumors	is	switch	to	aerobic	glycolysis	that	readilymeasured	by	[18f]-2-fluoro-2-deoxy-d-glucose	positron	emission	tomography(18f-fdg	pet)	imaging		co-mutations	in	the	kras	proto-oncogene	and	lkb1	tumorsuppressor	gene	are	frequent	events	lung	cancer	drive	hypermetabolic	glycolytic	tumor	growth	critical	pathway	regulating	metabolismof	these	mechanistic	target	rapamycin	(mtor)	whichcan	be	effectively	targeted	using	selective	catalytic	mtor	kinase	inhibitors	themtor	inhibitor	mln0128	suppresses	mice	bearing	with	andlkb1	referred	as	kl	therapy	response	isfirst	measured	18f-fdg	pet	computed	tomography	(ct)	before	andafter	delivery	utilizing	pet/ct	researchers	ableto	measure	dynamic	changes	glucose	metabolism	genetically	engineeredmouse	models	(gemms)	following	therapeutic	intervention	withtargeted	therapies	this	followed	ex	vivo	autoradiography	aquantitative	immunohistochemical	(qihc)	analysis	morphometric	software	theuse	qihc	enables	detection	quantification	distinct	thebiomarker	profiles	treatment	well	characterization	ofdistinct	pathologies	coupling	quantitative	histologyis	an	effective	strategy	identify	metabolic	responses	vivoin	mouse	disease
